Oct 5, 2026 08:19AM
Oct 5, 2026 07:01AM
Oct 5, 2026 07:00AM
Oct 2, 2026 06:04AM
Oct 2, 2026 02:30AM
Sep 29, 2026 12:12PM
Sep 28, 2026 05:33PM AstraZeneca invests $2B in Summit Therapeutics preferred shares
Sep 28, 2026 05:30PM
Sep 22, 2026 06:01AM
Sep 22, 2026 06:00AM
Sep 15, 2026 06:01AM
Sep 15, 2026 06:00AM
Sep 13, 2026 07:47PM
Sep 13, 2026 07:00AM Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study
Aug 25, 2026 06:39PM
Aug 25, 2026 06:00PM
Aug 25, 2026 07:02AM
Aug 25, 2026 07:00AM
Aug 12, 2026 09:22AM
Aug 12, 2026 09:22AM
Aug 5, 2026 07:00AM Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Jul 24, 2026 07:51AM
Jul 23, 2026 04:06PM
Jul 23, 2026 04:05PM
Jul 22, 2026 04:30PM
Jul 22, 2026 04:30PM
Jul 22, 2026 06:30AM
Jul 22, 2026 06:30AM Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Jul 16, 2026 08:00AM
Jul 14, 2026 07:00AM
Jul 14, 2026 07:00AM
Jun 9, 2026 04:47PM
Jun 9, 2026 04:47PM
Jun 4, 2026 04:30PM
Jun 1, 2026 02:53AM Summit's ivonescimab shows survival benefit in lung cancer trial
May 31, 2026 09:06AM
May 30, 2026 08:00AM
May 14, 2026 09:15AM
May 4, 2026 07:32AM
Apr 30, 2026 04:32PM
Mar 27, 2026 08:16AM
Mar 27, 2026 08:15AM Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
Mar 16, 2026 12:50AM
Feb 26, 2026 06:45PM
Feb 25, 2026 06:38AM
Feb 23, 2026 04:05PM
Feb 17, 2026 05:05PM
Feb 2, 2026 06:50AM
Jan 30, 2026 04:30PM Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 30, 2026 05:41AM

334,268 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All